Related Experiment Video
Updated: Sep 13, 2025
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
350
Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines
Safi G Alqatari1, Abrar J Alwaheed1, Manal A Hasan1
1Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, King Fahd University Hospital, Dammam 31441, Eastern Province, Saudi Arabia.
Medicina (Kaunas, Lithuania)
|July 30, 2025
Summary
New obesity drugs offer significant weight loss comparable to surgery. This review explores if a medication-first approach is now suitable, especially for patients with a BMI of 30-40 kg/m².
Area of Science:
- Metabolic disease research
- Pharmacological interventions
- Surgical procedures
Background:
- Obesity is a complex, chronic disease with major health impacts.
- Bariatric surgery has been the gold standard for significant weight loss.
- Emerging pharmacotherapies show remarkable efficacy, challenging surgical dominance.
Purpose of the Study:
- To review the evolution of bariatric surgery criteria.
- To assess the role of novel pharmacotherapies in obesity management.
- To compare surgery and advanced medications for efficacy, safety, and cost-effectiveness.
Main Methods:
- Narrative review of scientific literature.
- Analysis of current bariatric surgery guidelines.
- Comparative assessment of pharmacotherapy versus surgical outcomes.
Main Results:
- Novel pharmacotherapies achieve substantial weight loss (15-25%).
- These drugs approach the effectiveness of surgical interventions.
- The efficacy of medical treatments necessitates re-evaluating surgical eligibility.
Conclusions:
- A stepwise, pharmacotherapy-first approach may be justified for some patients (BMI 30-40 kg/m²).
- Personalized treatment strategies and integrated care pathways are future directions.
- Current bariatric surgery guidelines require re-evaluation in light of advanced medical therapies.
Related Concept Videos
01:28Drug Therapy
100
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
100
01:29Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193
01:21Inflammatory Bowel Disease V: Surgical Management
217
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
217
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
304
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
304
01:23Binge Eating Disorders
173
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
173
01:17Drugs for Treatment of Diarrhea-Predominant IBS
299
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
299